An interventional study of Offering Additional Resources to Promote Symptom Management in Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Supportive care
This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 208 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Abramson Cancer Center at Penn Medicine is the lead sponsor of 446 studies on the registry; 86 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 14 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic at which time they will be offered additional resources to promote symptom management. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
Behavioral: Offering Additional Resources to Promote Symptom Management
Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic where they will receive symptom management and supportive care. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
Participants will be offered additional resources to promote symptom management.
Quality of Life - McGill Quality of Life Questionnaire
Quality of life will be measured through the McGill Quality of Life Questionnaire Revised (MQOL-R). The questionnaire is 15 questions assessing overall and specific areas of quality of life.
Time frame: Baseline - 16 weeks
Feasibility of Accessing Additional Resources for Symptom Management
Feasibility will be measured by whether participants accessed the additional resources for symptom management.
Time frame: Baseline - 16 weeks
Acceptability of Accessing Additional Resources for Symptom Management
Acceptability will be measured by whether participants accessed the additional resources for symptom management.
Time frame: Baseline - 16 weeks
Symptom Severity
Symptom severity will be measured through the Edmonton Symptom Assessment System (ESAS). The survey is 10 questions assessing the severity of pain, nausea, depression, etc. on a 0 to 10 scale-in which a 0 representing best possible state/symptom absence and a 10 representing worst possible state.
Time frame: Baseline - 16 weeks
Medication Use
Medication use will be measured through a medication diary created for the study. The medication diary asks participants about recent medications, amounts, and dosages.
Time frame: Baseline - 16 weeks
Hospital-Free Days
Hospital-free days will be measured through examination of participant's electronic health record.
Time frame: Baseline - 16 weeks
Mortality
Mortality will be measured through examination of participant's electronic health record.
Time frame: Baseline - 16 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine